Cleverly Ann L相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

galunisertib（LY2157299 一水合物）是一种转化生长因子-β信号通路的小分子抑制剂，目前正在进行临床开发

期刊:Drug Design Development and Therapy

影响因子:5.1

doi:10.2147/DDDT.S86621

Herbertz Stephan, Sawyer J Scott, Stauber Anja J, Gueorguieva Ivelina, Driscoll Kyla E, Estrem Shawn T, Cleverly Ann L, Desaiah Durisala, Guba Susan C, Benhadji Karim A, Slapak Christopher A, Lahn Michael M

发表日期：2015

文献求助收藏

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

在首次人体剂量研究中，TGF-β受体I激酶抑制剂LY2157299一水合物对癌症患者的心脏安全性

期刊:Cardiovascular Toxicology

影响因子:3.7

doi:10.1007/s12012-014-9297-4

Kovacs, Richard J; Maldonado, Giuliana; Azaro, Analia; Fernández, Maria S; Romero, Federico L; Sepulveda-Sánchez, Juan M; Corretti, Mary; Carducci, Michael; Dolan, Melda; Gueorguieva, Ivelina; Cleverly, Ann L; Pillay, N Sokalingum; Baselga, Jose; Lahn, Michael M

发表日期：2015

文献求助收藏

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

基于药代动力学/药效学模型确定新型TGF-β抑制剂LY2157299一水合物的治疗窗口

期刊:British Journal of Clinical Pharmacology

doi:10.1111/bcp.12256

Gueorguieva, Ivelina; Cleverly, Ann L; Stauber, Anja; Sada Pillay, N; Rodon, Jordi A; Miles, Colin P; Yingling, Jonathan M; Lahn, Michael M

发表日期：2014

文献求助收藏

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

一项针对难治性实体瘤患者的新型抗癌化合物tasisulam钠（LY573636钠）的I期研究

期刊:Cancer Chemotherapy and Pharmacology

影响因子:2.3

doi:10.1007/s00280-011-1593-0

Simon, George R; Ilaria, Robert L Jr; Sovak, Mika A; Williams, Charles C; Haura, Eric B; Cleverly, Ann L; Sykes, Amanda K; Wagner, Margaret M; de Alwis, Dinesh P; Slapak, Christopher A; Miller, Mary A; Spriggs, David R

发表日期：2011

文献求助收藏